Bhageria Industries obtains EDQM GMP approval for Dexamethasone production at Vapi plant
European Directorate for the Quality of Medicines & Healthcare attests compliance with EU GMP standards under CEP No. 2024-138 following February 2026 inspection
Bhageria Industries Limited received the Good Manufacturing Practice (GMP) attestation from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its Vapi facility, confirming compliance with EU GMP standards for manufacturing Dexamethasone under CEP No. 2024-138.
Bhageria Industries Limited
Legal / Regulatory
Bhageria Industries Limited announced receipt of the Good Manufacturing Practice (GMP) attestation from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its manufacturing site in Vapi, Gujarat, related to Dexamethasone production under Certificate of Suitability (CEP) No. 2024-138.
The EDQM conducted a GMP inspection at Bhageria's Vapi facility from February 4 to February 6, 2026. This attestation confirms the company's adherence to the European Union Good Manufacturing Practice requirements as part of the CEP certification framework for Dexamethasone manufacture.
The manufacturing facility is located at Plot No 6102/10, GIDC IV Phase, Vapi, Gujarat 396195, India.
This approval is significant for Bhageria Industries as it ensures compliance with stringent European standards, enabling continued or expanded supply of Dexamethasone in regulated markets.
Highlights
- Received EDQM Good Manufacturing Practice (GMP) attestation under Reference Number INSP 2025-052-PO1.
- Inspection conducted from February 4 to February 6, 2026, at the Vapi manufacturing site.
- Approval pertains specifically to Dexamethasone produced under Certificate of Suitability (CEP) No. 2024-138.
- Confirms compliance with European GMP standards relevant to medicine quality and healthcare requirements.
Key Data Snapshot
What happened
- Bhageria Industries Limited received the Good Manufacturing Practice (GMP) attestation from the European Directorate for the Quality of Medicines & Healthcare (EDQM).
- The attestation confirms compliance with applicable European GMP regulations under the Certificate of Suitability framework.
- The approval pertains to the company's manufacturing of Dexamethasone at its Vapi facility in Gujarat.
Key details
- The EDQM inspection was held from February 4 to February 6, 2026, at Bhageria’s Vapi manufacturing site.
- The inspection reference number is INSP 2025-052-PO1.
- Compliance is specifically related to Dexamethasone produced under Certificate of Suitability number 2024-138.
Regulatory and governance context
- The attestation demonstrates conformity with European Union Good Manufacturing Practice standards, essential for maintaining supply authorization in European and other regulated markets.
- The Certificate of Suitability (CEP) confirms that the active pharmaceutical ingredient meets the quality standards required by the European Pharmacopoeia.
Highlights
- Received EDQM Good Manufacturing Practice (GMP) attestation under Reference Number INSP 2025-052-PO1.
- Inspection conducted from February 4 to February 6, 2026, at the Vapi manufacturing site.
- Approval pertains specifically to Dexamethasone produced under Certificate of Suitability (CEP) No. 2024-138.
- Confirms compliance with European GMP standards relevant to medicine quality and healthcare requirements.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Regulation 30
- European Union Good Manufacturing Practice (EU GMP) requirements
- Certificate of Suitability (CEP) framework by EDQM
More News on Legal / Regulatory
View allLatest corporate announcements and market updates in Legal / Regulatory.
Ellenbarrie Industrial Gases Limited's IPO Proceeds Fully Compliant Per CRISIL Monitoring Report for Q2 2026
Ellenbarrie Industrial Gases Limited has submitted the Monitoring Agency Report issued by CRISIL Ratings Limited for the quarter ended September 30, 2026, confirming that the company utilized IPO proceeds in line with the objects stated in its offer document.
Read Full StoryUnited Breweries Secures BIADA Approval to Restore Patna Brewery Land Lease under Amnesty Policy 2025
United Breweries Limited has received an official order from the Bihar Industrial Area Development Authority (BIADA) restoring the allotment of its 42-acre leasehold land at Kopakalan Industrial Area in Patna, enabling the company to recommence brewery operations under specified conditions.
Read Full StoryDeepak Fertilisers Wins Dismissal of Income Tax Department Appeals on ₹215 Crore Dispute for AY 2013-14 to AY 2018-19
Deepak Fertilisers and Petrochemicals Corporation Limited reported that the Income-tax Appellate Tribunal (ITAT), Mumbai, dismissed the Income Tax Department’s appeals regarding disputed taxable income totaling ₹215 Crores for assessment years 2013-14 to 2018-19, confirming the favorable earlier order by the Commissioner of Income Tax (Appeals) dated 8 January 2026.
Read Full Story